What Is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is a growth hormone secretagogue combination supplied by Peptegrity for research and educational purposes. This page provides a factual educational overview of CJC-1295 + Ipamorelin, including its classification, biological target, research background, terminology and published study context. It is not a product page and does not provide dosing instructions, treatment recommendations or personal-use guidance.
Type of compound
CJC-1295 and Ipamorelin are classified as a growth hormone secretagogue combination. This pairing involves a growth hormone-releasing hormone (GHRH) analogue and a selective ghrelin receptor agonist.
Biological target and mechanism
CJC-1295 functions as a long-acting analogue of GHRH, designed to stimulate the pituitary gland by binding to the GHRH receptor [1, 2]. Ipamorelin acts as a selective growth hormone secretagogue that stimulates growth hormone release through the ghrelin receptor pathway without significantly impacting other pituitary hormones [3].
Research background
Research into this combination focuses on the synergistic effects of combining a long-acting GHRH analogue with a selective secretagogue. Studies have examined how these compounds interact to modulate the pulsatile secretion of growth hormone within controlled models [2, 4].
Current research and development status
Both CJC-1295 and Ipamorelin are strictly investigational compounds used for laboratory research purposes. They have not been approved by the FDA or other regulatory bodies for human therapeutic use.
Published research context
Clinical research has investigated the pharmacokinetics and long-acting properties of CJC-1295 in healthy adult subjects [1]. Additional studies have explored the specific binding characteristics of Ipamorelin and its role in selective growth hormone stimulation [3]. Ongoing research continues to examine the stability and systemic effects of these peptides in preclinical models [4].
Relevant terminology
GHRH analogues are synthetic peptides modeled after naturally occurring growth hormone-releasing hormones. A secretagogue is a substance that induces or increases the secretion of another substance, in this case, growth hormone.
Storage and handling terminology
Peptides are typically stored as lyophilized powders in a cool, dry environment to maintain molecular stability. Once reconstituted in a suitable solvent, they are often kept in refrigerated conditions to prevent degradation.
Testing and Certificate of Analysis (COA)
A Certificate of Analysis (COA) is a document issued by quality control laboratories that confirms the purity and identity of a chemical batch. Researchers should verify that compounds are accompanied by analytical data, such as HPLC or Mass Spectrometry results, to confirm the integrity of the research material.
Regulatory status
These compounds are categorized as research chemicals and are not authorized for clinical or medicinal use. Their distribution is limited to laboratory, educational, and research facilities for scientific study only.
This page is for research and educational purposes only. It is not intended to provide medical advice, dosing instructions, or treatment recommendations, and does not represent any product as approved to diagnose, treat, cure or prevent any disease. Compounds described here may be investigational or unapproved medicines; regulatory status is summarised for information only.
Frequently asked questions
What is the primary function of CJC-1295 in research?
CJC-1295 is studied as a long-acting GHRH analogue that mimics the endogenous hormone to stimulate growth hormone secretion over an extended duration [1, 2].
How does Ipamorelin differ from other secretagogues?
Ipamorelin is characterized by its high selectivity, meaning it effectively stimulates growth hormone release while demonstrating minimal effect on other hormone levels in laboratory models [3].
Why are CJC-1295 and Ipamorelin studied together?
Researchers study the combination to evaluate how the synergistic action of a long-acting GHRH analogue and a selective secretagogue influences pituitary secretion pathways [2, 3].
Is this combination an approved medication?
No, CJC-1295 and Ipamorelin are investigational peptides and have not been approved for any human therapeutic applications by regulatory agencies.
What does a Certificate of Analysis indicate for these peptides?
A COA provides verification of the compound's purity level and chemical identity, ensuring that the material meets specific laboratory standards for research use.
References
- 1.Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsPubMed
- 2.Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogPubMed
- 3.Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology
- 4.Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mousePubMed
